List of Excipients in Branded Drug ZULRESSO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sage Therapeutics Inc	ZULRESSO	brexanolone	72152-547	BETADEX SULFOBUTYL ETHER SODIUM	2029-03-13
Sage Therapeutics Inc	ZULRESSO	brexanolone	72152-547	CITRIC ACID MONOHYDRATE	2029-03-13
Sage Therapeutics Inc	ZULRESSO	brexanolone	72152-547	TRISODIUM CITRATE DIHYDRATE	2029-03-13

ZULRESSO Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

ZULRESSO is an intravenous brexanolone formulation whose commercial value depends heavily on its excipient system, hospital administration requirements, and the limited practicality of a 60-hour infusion. The formulation uses betadex sulfobutyl ether sodium, also known as sulfobutylether-beta-cyclodextrin sodium or SBECD, to solubilize brexanolone in an aqueous injectable product. The strongest commercial opportunities are improved ready-to-use hospital presentations, lower-burden administration systems, renal-risk mitigation, and alternative brexanolone dosage forms.

What is the ZULRESSO formulation and which excipients does it contain?

ZULRESSO is a preservative-free injection containing 5 mg/mL of brexanolone. Its principal excipient is betadex sulfobutyl ether sodium, which enables the poorly water-soluble neuroactive steroid to remain in solution. The formulation also contains citric acid monohydrate, sodium hydroxide for pH adjustment, and water for injection (U.S. Food and Drug Administration [FDA], 2019).

Formulation attribute	ZULRESSO profile
Active ingredient	Brexanolone
Strength	5 mg/mL
Dosage form	Intravenous injection
Administration	Continuous infusion over 60 hours
Primary solubilizer	Betadex sulfobutyl ether sodium
Other formulation components	Citric acid monohydrate, sodium hydroxide, water for injection
Preservative	None
Indication	Postpartum depression in adults
Regulatory pathway	New drug application 211371
Approval date	March 19, 2019
Distribution controls	Risk Evaluation and Mitigation Strategy, including monitored administration

SBECD is a modified cyclodextrin that improves aqueous solubility by forming inclusion complexes with hydrophobic drug molecules. This approach is common in injectable products for compounds that cannot achieve clinically useful concentrations through simple pH adjustment or cosolvent systems.

Why is SBECD commercially important for brexanolone?

SBECD is central to the current ZULRESSO product architecture. Brexanolone is a steroidal molecule with limited aqueous solubility. A cyclodextrin complex permits an aqueous intravenous product without relying on high concentrations of ethanol, propylene glycol, polyethylene glycol, surfactants, or lipid emulsions.

The excipient strategy creates several benefits:

1. It supports a clear, aqueous, preservative-free injection.
2. It avoids a lipid-based emulsion that could create separate handling and compatibility issues.
3. It allows controlled delivery through an infusion pump.
4. It provides a platform for concentration, stability, and container-closure optimization.

The same strategy also creates constraints. SBECD exposure increases with dose and infusion duration. The FDA label identifies renal impairment as a relevant safety consideration because cyclodextrin clearance is reduced in patients with severe renal dysfunction. ZULRESSO is not recommended in patients with estimated glomerular filtration rates below 15 mL/min/1.73 m², including patients receiving dialysis (FDA, 2019).

For a commercial successor, the excipient problem is therefore not limited to solubility. A new formulation must preserve solubilization while reducing excipient burden, improving renal suitability, or eliminating the need for prolonged infusion.

What formulation patents and intellectual-property barriers protect ZULRESSO?

The commercial protection for ZULRESSO can involve several patent categories:

Active pharmaceutical ingredient and steroid chemistry

Brexanolone is a naturally occurring neuroactive steroid, which limits the scope available for basic composition-of-matter protection compared with a novel synthetic small molecule. Protection is more likely to focus on pharmaceutical compositions, purity, dosage levels, manufacturing processes, and therapeutic use.

Cyclodextrin-containing formulations

A formulation using SBECD or another cyclodextrin can support patents directed to:

• Brexanolone-to-cyclodextrin ratios
• Concentration ranges
• pH and buffer systems
• Infusion stability
• Container-closure compatibility
• Dilution into saline
• Protection from precipitation or adsorption
• Administration protocols

A generic applicant could attempt to avoid these claims by using a different solubilizer, a different cyclodextrin derivative, a lipid system, a cosolvent system, or a chemically modified brexanolone formulation.

Method-of-use patents

Potential method-of-use claims may cover treatment of postpartum depression with brexanolone, dosing schedules, titration, infusion duration, patient selection, and monitoring. Such claims can create Paragraph IV litigation risk if listed in the FDA Orange Book and asserted against an abbreviated new drug application.

Manufacturing and process patents

Process claims may cover:

• Complexation of brexanolone with SBECD
• Removal of particulates and degradants
• Control of steroid impurities
• Sterile filtration
• Aseptic filling
• Long-term storage conditions
• Preparation of diluted infusion solutions

These claims may create manufacturing barriers even when a competitor can design around the final formulation claims.

The precise patent term and Orange Book exposure must be assessed against the current FDA Orange Book and USPTO records. FDA approval materials identify the product and NDA but do not provide a complete patent-landscape analysis (FDA, 2019; FDA, 2024).

When does ZULRESSO lose regulatory exclusivity?

The principal regulatory milestones are:

Exclusivity or regulatory event	Date or status
FDA approval	March 19, 2019
New chemical entity exclusivity	Approximately five years from approval, subject to applicable pediatric adjustments
Orphan-drug exclusivity	Generally seven years from approval if applicable to the approved indication
Earliest ordinary NCE generic filing window	Typically four years after approval for a Paragraph IV ANDA filing
Biosimilar pathway	Not applicable because brexanolone is a small-molecule drug
REMS	Required for monitored administration and sedation-related risks

The orphan-drug exclusivity period, if measured from the 2019 approval for the qualifying postpartum-depression indication, would run to approximately March 2026. Orphan exclusivity does not prevent all competing products. It is indication-specific and does not necessarily block an applicant pursuing a different indication, dosage form, or legally distinct use.

NCE exclusivity would generally have ended in 2024, subject to any pediatric extension. Patent rights can continue beyond regulatory exclusivity and remain the primary timing issue for a conventional generic launch.

What Paragraph IV challenges and generic-entry risks exist for ZULRESSO?

A conventional generic would need to match the reference product in active ingredient, dosage form, route, strength, and pharmaceutical equivalence. The applicant would also need to address listed patents through certification under the Hatch-Waxman framework.

The principal generic-entry risks are:

Formulation equivalence

A generic using SBECD may face formulation patent claims covering the complex, concentration, pH, or stability profile. A non-SBECD product may avoid those claims but introduce new development risk, including precipitation, particulate formation, infusion compatibility, or inadequate shelf life.

Clinical administration

The product is administered as a controlled infusion for 60 hours and requires patient monitoring for excessive sedation, loss of consciousness, and oxygen desaturation. A generic must replicate the reference product’s labeling and administration instructions unless it obtains approval for a different product profile.

Facility and distribution requirements

ZULRESSO is administered in certified healthcare settings under a REMS. This reduces the value of a low-cost generic unless hospitals have sufficient demand and the product offers operational advantages.

Limited market size

The postpartum-depression indication is clinically important but the initial product’s commercial market has been constrained by inpatient administration, staffing requirements, infusion-pump utilization, and the availability of oral antidepressants. These factors reduce the expected return on a technically complex generic.

A Paragraph IV challenger would have the strongest commercial position if it combines patent design-around certainty with a simpler presentation, such as a ready-to-administer bag, higher concentration, or a formulation compatible with shorter infusion duration.

What commercial opportunities exist for ZULRESSO excipient suppliers?

The excipient opportunity is broader than supplying SBECD to the reference product. Suppliers can compete across formulation redesign, hospital logistics, and lifecycle management.

SBECD supply and quality differentiation

A qualified SBECD supplier can differentiate through:

• Low endotoxin grades
• Tighter control of degree of substitution
• Reduced residual solvents and metals
• Injectable-grade documentation
• Global regulatory support
• Reliable supply for sterile manufacturing
• Stability data in infusion containers

Because cyclodextrin quality can affect complexation, osmolality, impurity profiles, and stability, switching suppliers may require comparability work even when the chemical excipient is unchanged.

Ready-to-use infusion presentations

The current administration model requires preparation and continuous infusion. A ready-to-use bag or prefilled system could reduce pharmacy compounding, handling time, and dosing errors. Commercial products could include:

• Pre-diluted infusion bags
• Single-use pharmacy containers
• Smaller-volume bags for titration
• Barcode-enabled products
• Closed-system transfer configurations
• Container systems with improved light and oxygen protection

The best opportunity is likely operational rather than purely chemical. Hospitals may pay for reduced preparation and monitoring complexity if the formulation maintains stability and compatibility.

Higher-concentration formulations

A higher-concentration formulation could reduce infusion volume and storage burden. It would need to maintain solubility and avoid excessive SBECD exposure. The key development variables would include:

• Brexanolone/SBECD molar ratio
• Total cyclodextrin dose
• Osmolality
• pH
• Infusion rate
• Dilution requirements
• Compatibility with tubing and pumps

A concentration increase that does not reduce the 60-hour treatment period would offer a modest benefit. The commercial value would be greater if it enabled a smaller device, fewer bag changes, or outpatient administration.

Alternative solubilizer systems

Potential alternatives include hydroxypropyl-beta-cyclodextrin, other sulfobutylated cyclodextrins, surfactant systems, lipid formulations, cosolvent systems, and nanoparticle or nanosuspension technologies. Each option must address parenteral safety, precipitation risk, sterilization, and manufacturing scale.

A non-cyclodextrin formulation could have the clearest patent-design-around value, but it would also face the highest technical risk.

What formulations could improve ZULRESSO’s commercial position?

Development concept	Potential benefit	Main barrier
Ready-to-use SBECD infusion bag	Less pharmacy preparation	Stability and container compatibility
Higher-concentration injection	Lower infusion volume	Solubility and renal excipient exposure
Reduced-SBECD formulation	Broader renal suitability	Drug precipitation and shelf-life risk
Alternative cyclodextrin	Patent design-around	New safety and comparability package
Subcutaneous depot	Avoids prolonged IV infusion	Local tolerability and dose delivery
Intramuscular formulation	More flexible administration	High dose and injection-volume constraints
Oral formulation	Large outpatient market	First-pass metabolism and bioavailability
Intranasal formulation	Rapid central nervous system delivery	Device, local tolerability, dose reproducibility
Transdermal system	Extended exposure	Steroid permeability and patch loading

The most realistic near-term opportunity is an improved intravenous product. Oral, intranasal, transdermal, and depot products could create substantially larger markets but would require new pharmacokinetic and clinical programs rather than simple generic substitution.

How does ZULRESSO compare with competing postpartum-depression therapies?

ZULRESSO competes with oral antidepressants and zuranolone, an oral neuroactive steroid approved by the FDA in 2023 for postpartum depression. Zuranolone offers a 14-day oral regimen, while ZULRESSO requires a 60-hour continuous intravenous infusion in a monitored setting (FDA, 2023).

Attribute	ZULRESSO	Zuranolone
Active ingredient	Brexanolone	Zuranolone
Route	Intravenous	Oral
Treatment duration	60-hour infusion	14-day course
Administration setting	Monitored healthcare facility	Outpatient use, subject to labeling
Excipient strategy	SBECD aqueous injection	Oral solid or capsule formulation
Main commercial barrier	Infusion logistics and cost	Oral safety, access, and reimbursement
Generic or biosimilar status	Small-molecule generic pathway	Small-molecule generic pathway
Formulation opportunity	Ready-to-use, concentrated, lower-excipient IV	Improved oral bioavailability and solid-state control

Zuranolone changes the commercial benchmark for brexanolone. Any new ZULRESSO formulation must offer a clear advantage in speed, efficacy, safety, adherence, administration setting, or cost.

What FDA regulatory status affects commercial development?

ZULRESSO was approved under NDA 211371 with a REMS because of excessive sedation and the risk of sudden loss of consciousness. Patients require continuous pulse oximetry and monitoring during administration. The product label also addresses interruption of therapy, dose titration, and administration through an infusion pump (FDA, 2019).

An improved formulation could require:

• A supplemental NDA if the active ingredient and core product remain substantially unchanged
• New clinical pharmacology data for altered concentration or excipient exposure
• Container-closure and extractables/leachables studies
• Particulate and sterility validation
• Revised REMS materials if administration changes
• New clinical studies for a different route or treatment duration

A true alternative dosage form would normally require a new NDA or a substantial development program rather than a simple formulation supplement.

What manufacturing and IP barriers affect commercial entry?

The main barriers are technical and operational:

1. Brexanolone solubility must remain controlled throughout shelf life and infusion.
2. SBECD quality must meet injectable standards.
3. The product must remain compatible with saline dilution, tubing, syringes, and infusion pumps.
4. Sterile filtration and aseptic filling must control steroid-related impurities.
5. The formulation must avoid precipitation during preparation and administration.
6. Patent claims may cover the excipient combination, concentration, process, or method of use.
7. The market must support the cost of a specialized sterile product.

These barriers favor companies with sterile injectable capacity, cyclodextrin formulation expertise, hospital distribution infrastructure, and experience with FDA post-approval changes.

How strong is the ZULRESSO patent and lifecycle estate?

The estate is commercially meaningful but structurally narrower than the estate for a novel chemical entity. Brexanolone’s steroid identity limits basic composition-of-matter leverage. The more defensible areas are likely formulation, manufacturing, dosage regimen, and postpartum-depression use claims.

Patent strength is highest where claims are narrow enough to withstand validity review but broad enough to capture SBECD-based alternatives and clinically relevant concentration ranges. It is weaker where competitors can use a different solubilizer or dosage form without affecting pharmacokinetic performance.

The most valuable lifecycle strategy is a formulation patent combined with regulatory differentiation. A patent covering a ready-to-use, stable, lower-excipient or higher-concentration product would have greater commercial value than a claim that merely repeats the existing infusion architecture.

Key Takeaways

• ZULRESSO uses SBECD as its principal solubilizing excipient for brexanolone.
• The excipient enables an aqueous injectable product but contributes renal-exposure and formulation-design constraints.
• The largest near-term opportunity is a ready-to-use or higher-concentration intravenous presentation.
• A lower-SBECD or non-cyclodextrin formulation could create patent-design-around value but carries higher technical risk.
• ZULRESSO’s orphan exclusivity would generally extend to approximately March 2026 from the 2019 approval, while patent expiry may occur later.
• Biosimilar competition does not apply because brexanolone is a small-molecule drug.
• Generic entry is limited by formulation patents, sterile manufacturing requirements, REMS obligations, and the economics of a 60-hour infusion.
• Zuranolone is the principal commercial comparator because its oral 14-day regimen addresses the administration burden of ZULRESSO.

FAQs

Can SBECD be replaced in a generic ZULRESSO formulation?

Yes. A generic applicant could pursue a different solubilizer, but it would need to demonstrate adequate solubility, stability, sterility, compatibility, and bioequivalence. A different excipient may also avoid some formulation patent claims.

Does ZULRESSO require a biologic license application?

No. Brexanolone is a small-molecule drug approved under an NDA. Competitors would generally use the ANDA pathway for a qualifying generic or an NDA pathway for a materially different formulation or route.

Could a ready-to-use ZULRESSO bag support premium pricing?

Potentially. The commercial value would depend on reduced pharmacy labor, fewer preparation steps, lower contamination risk, fewer bag changes, and reimbursement treatment. A ready-to-use presentation would need validated stability after shipping and administration.

Is renal impairment the main safety limitation of SBECD in ZULRESSO?

It is a significant formulation-related concern because SBECD is renally cleared. The product label restricts use in severe renal impairment. Sedation, loss of consciousness, and oxygen desaturation remain important active-drug and administration risks.

Would an oral brexanolone product compete directly with zuranolone?

Yes. An oral brexanolone formulation would compete primarily on onset, efficacy, treatment duration, safety, and dosing convenience. It would require a new formulation and clinical development strategy because oral delivery changes exposure and pharmacokinetics.

References

1. U.S. Food and Drug Administration. (2019). ZULRESSO (brexanolone) injection, prescribing information.
2. U.S. Food and Drug Administration. (2019, March 19). FDA approves first treatment for postpartum depression.
3. U.S. Food and Drug Administration. (2023). ZURZUVAE (zuranolone) capsules, prescribing information.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. Sage Therapeutics, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.